You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Govt nod to commercial export of Covishield, Covaxin amid sufficient stock

However, the quantity of Covid vaccines to be exported will be decided by the government every month to ensure there is no dearth of domestic availability

Coronavirus | Coronavirus Tests | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

India too had opened diplomatic dialogues with the European Union (EU) after the EU Digital Covid Certificate framework recognised the AstraZeneca-Oxford vaccine, but not Covishield.

The Union government has allowed commercial export of Covishield and Covaxin considering the sufficient stock of the COVID-19 vaccines available with states and Union Territories as well as with manufacturers, official sources said on Thursday.

However, the quantity of Covid vaccines to be exported will be decided by the government every month to ensure there is no dearth of domestic availability.

India recently resumed Covid vaccine supply to the UN-backed COVAX with the government allowing Serum Institute of India (SII) to export 50 Lakh doses of Covishield to Nepal, Tajikistan, Bangladesh and Mozambique.

The Covishield shipment will reach Nepal and Tajikistan this week.

"More than 22.72 crore balance and unutilized COVID-19 vaccine doses are still available with the states and Union Territories. The vaccine production is increasing and there will be surplus supplies.

"Keeping this in mind, a decision has been taken to allow commercial export of Covishield and Covaxin," an official source told PTI.

Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII had recently communicated to the Union Health Ministry that the Pune-based firm has 24,89,15,000 doses of Covishield and the stock is increasing every day.

The official, however stressed, "The quantity of vaccines to be exported will be decided by the government on a monthly basis to ensure that domestic availability is not hampered in any way."

About 31 crore doses of Covishield and Covaxin are expected to be received by the government from SII and Bharat Biotech in December, while Zydus Cadila is likely to supply around two crore jabs of its three-dose Covid vaccine ZyCoV-D by that time.

The government recently permitted the export of 2 crore doses of COVID-19 vaccine Covovax, produced in India by SII, to Indonesia. The jab is yet to be approved for emergency use in the country, according to official sources.

The first shipment of Covovax will reach Indonesia this week.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 25 2021. 19:21 IST